|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
68,990,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Bicycle Therapeutics is a holding company. Through its subsidiaries, Co. is a clinical-stage biopharmaceutical company developing a class of medicines, which it refers to as Bicycles. Bicycles are a therapeutic modality combining the pharmacology associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Co. is evaluating BT5528, a Bicycle Toxin Conjugate (BTC) targeting Ephrin type-A receptor 2, BT8009, a BTC targeting Nectin-4, and BT7480, a Bicycle tumor-targeted immune cell agonist® targeting Nectin-4 and agonizing CD137. In addition, BT1718, a BTC that is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
7,268 |
14,490 |
37,488 |
61,094 |
Total Sell Value |
$142,744 |
$314,362 |
$724,634 |
$1,369,761 |
Total People Sold |
7 |
7 |
7 |
9 |
Total Sell Transactions |
7 |
14 |
26 |
45 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Cambridge Innovation Capital (jersey) Ltd |
10% Owner |
|
2019-05-28 |
4 |
A |
$0.00 |
$0 |
D/D |
1,311,564 |
1,437,151 |
|
- |
|
Cambridge Innovation Capital (jersey) Ltd |
10% Owner |
|
2019-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
125,587 |
1,207,410 |
|
- |
|
Glaxosmithkline Plc |
Director |
|
2019-05-28 |
4 |
B |
$14.00 |
$5,399,996 |
I/I |
385,714 |
1,915,275 |
2.25 |
- |
|
Glaxosmithkline Plc |
Director |
|
2019-05-28 |
4 |
A |
$0.00 |
$0 |
I/I |
1,529,561 |
1,529,561 |
|
- |
|
Vertex Global Healthcare Fund I Pte Ltd. |
10% Owner |
|
2019-05-28 |
4 |
A |
$0.00 |
$0 |
D/D |
1,479,500 |
1,621,168 |
|
- |
|
Vertex Global Healthcare Fund I Pte Ltd. |
10% Owner |
|
2019-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
141,668 |
1,414,401 |
|
- |
|
Novartis Ag |
10% Owner |
|
2019-05-28 |
4 |
B |
$14.00 |
$2,360,820 |
D/D |
168,630 |
1,769,641 |
2.45 |
- |
|
Novartis Ag |
10% Owner |
|
2019-05-28 |
4 |
A |
$0.00 |
$0 |
D/D |
1,529,561 |
1,601,011 |
|
- |
|
Novartis Ag |
10% Owner |
|
2019-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
71,450 |
964,645 |
|
- |
|
Harland Deborah |
Director |
|
2019-05-28 |
4 |
B |
$14.00 |
$5,399,996 |
I/I |
385,714 |
1,915,275 |
2.1 |
- |
|
Harland Deborah |
Director |
|
2019-05-28 |
4 |
A |
$0.00 |
$0 |
I/I |
1,529,561 |
1,529,561 |
|
- |
|
Sv Life Sciences Fund V Strategic Partners, L.p. |
10% Owner |
|
2019-05-28 |
4 |
B |
$14.00 |
$5,400,010 |
I/I |
385,715 |
39,637 |
1.5 |
- |
|
Sv Life Sciences Fund V Strategic Partners, L.p. |
10% Owner |
|
2019-05-28 |
4 |
A |
$0.00 |
$0 |
I/I |
1,529,559 |
31,654 |
|
- |
|
Winter Gregory Paul |
Director |
|
2019-05-28 |
4 |
A |
$0.00 |
$0 |
D/D |
42,870 |
92,477 |
|
- |
|
Anstey Michael |
Director |
|
2019-05-28 |
4 |
B |
$14.00 |
$4,400,004 |
I/I |
314,286 |
1,751,437 |
2.1 |
- |
|
Anstey Michael |
Director |
|
2019-05-28 |
4 |
A |
$0.00 |
$0 |
I/I |
1,311,564 |
1,437,151 |
|
- |
|
Anstey Michael |
Director |
|
2019-05-28 |
4 |
OE |
$0.00 |
$0 |
I/I |
125,587 |
1,207,410 |
|
- |
|
Ng Carolyn |
Director |
|
2019-05-28 |
4 |
A |
$0.00 |
$0 |
I/I |
1,479,500 |
1,621,168 |
|
- |
|
Ng Carolyn |
Director |
|
2019-05-28 |
4 |
OE |
$0.00 |
$0 |
I/I |
141,668 |
1,414,401 |
|
- |
|
Bingham Kate |
Director |
|
2019-05-28 |
4 |
B |
$14.00 |
$5,400,010 |
I/I |
385,715 |
39,637 |
2.1 |
- |
|
Bingham Kate |
Director |
|
2019-05-28 |
4 |
A |
$0.00 |
$0 |
I/I |
1,529,559 |
31,654 |
|
- |
|
Ng Carolyn |
Director |
|
2019-05-27 |
4 |
B |
$14.00 |
$8,000,006 |
I/I |
571,429 |
571,429 |
2.1 |
- |
|
Skynner Michael |
Chief Operating OfficerOfficer |
|
2019-05-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
41,123 |
|
- |
|
Lee Kevin |
Chief Executive OfficerOfficer |
|
2019-05-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
275,085 |
|
- |
|
Keen Nicholas |
Chief Scientific OfficerOffice |
|
2019-05-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
48,321 |
|
- |
|
226 Records found
|
|
Page 9 of 10 |
|
|